LRMR Larimar Therapeutics
- 6.640
- +0.460+7.44%
- 6.700
- +0.060+0.90%
Larimar Therapeutics News
Express News | Larimar Therapeutics Shares Hit Session Low With Volume Pickup, Last Down 5.3% at $6.04
Larimar Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Larimar Therapeutics Presents Additional Data From Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024
Is Larimar Therapeutics (LRMR) the Best Multibagger Stock to Buy Heading Into 2025?
Express News | Watching Larimar Therapeutics; Traders Circulate Stock Picked By Zacks Under $10 Newsletter
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26
Express News | Larimar Therapeutics Inc : Guggenheim Raises Target Price to $26 From $25
Larimar Therapeutics Analyst Ratings
Citi Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $14
Larimar Therapeutics | 10-Q: Q3 2024 Earnings Report
H.C. Wainwright Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $15
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $36
Larimar Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results.
Larimar Therapeutics GAAP EPS of -$0.24 Beats by $0.14
Larimar Therapeutics Sees Projected Cash Runway Into 2026 >LRMR
Larimar Therapeutics: Initiation of Global Confirmatory/registration Study Planned Mid-2025 >LRMR
Larimar Therapeutics: Initiation of PK Run-In Study in Adolescents on Track by Yr-end 2024 >LRMR
Larimar Therapeutics: Nomlabofusp Program Update Expected Mid-Dec to Include Available Safety, Pharmacokinetic and Frataxin Data >LRMR
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Express News | Larimar Therapeutics Q3 Net Income USD -15.499 Million
Analysis
Price Target
No Data
No Data